Armistice Capital LLC Makes New $57,000 Investment in NextCure, Inc. (NASDAQ:NXTC)

Armistice Capital LLC bought a new stake in NextCure, Inc. (NASDAQ:NXTC) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,000 shares of the company’s stock, valued at approximately $57,000. Armistice Capital LLC owned 0.13% of NextCure as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in shares of NextCure by 15.4% in the 2nd quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock worth $735,000 after purchasing an additional 61,744 shares during the last quarter. Cable Car Capital LLC acquired a new position in shares of NextCure during the fourth quarter valued at $702,000. Vanguard Group Inc. boosted its stake in shares of NextCure by 9.3% in the 1st quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock valued at $2,202,000 after purchasing an additional 83,700 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in NextCure in the first quarter valued at approximately $3,031,000. Finally, Logos Global Management LP grew its stake in shares of NextCure by 29.9% during the second quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock worth $3,975,000 after purchasing an additional 575,000 shares during the period. 42.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on NXTC shares. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of NextCure in a report on Friday, May 31st. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 target price on shares of NextCure in a report on Friday, August 2nd.

NextCure Trading Down 2.1 %

NASDAQ:NXTC opened at $1.38 on Friday. The stock has a market cap of $38.60 million, a price-to-earnings ratio of -0.61 and a beta of 0.79. The stock has a 50-day moving average price of $1.52 and a two-hundred day moving average price of $1.59. NextCure, Inc. has a 1 year low of $0.98 and a 1 year high of $2.57.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, August 1st. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.19). Sell-side analysts forecast that NextCure, Inc. will post -1.79 earnings per share for the current year.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.